4DMedical reports full year revenue of $7.2M

• 4DMedical announced full-year operating revenue of $7.2 million for FY26, representing a 23% increase compared to the prior corresponding period.
• The company's share price closed up 12.15% at $3.60 following the quarterly report and financial release.
• Management attributes the revenue growth to increased paid scan volumes and strong margins exceeding 90%.
• 4DMedical (ASX:4DX) reported operating revenue of $278 million as of June 30.

The company achieved a 23% revenue increase compared to the prior corresponding period driven by higher paid scan volumes.

The firm delivered SaaS products across 540 sites globally and recorded 105,970 scans in the fourth quarter of fiscal 2026, marking a 43% increase year-on-year.

The business stated that recent commercial agreements and clinical programmes are expected to expand its addressable market segments.

Following the announcement, the 4DMedical share price was up at $3.60.

The company specialises in respiratory imaging technology designed to assess lung function and support pulmonary drug development.

Recent corporate actions include entering the U.S. outpatient market via SimonMed Imaging, acquiring European lung imaging company Contextflow, and establishing partnership agreements with Azra AI.